The name of the company has been changed from Laurel Organics Limited to Kimia Biosciences Limited with effect from 04-01-2019 pursuant to the Scheme of Arrangement for Amalgamation of Kimia Biosciences Limited-Transferor Company-with Laurel Organics Limited -Transferee Company-as per the approval and Order of Honrable NCLT Chandigarh.
logo
+91-11-4706 3600
info@kimiabiosciences.com

Fimasartan Trihydrate Potassium

FIMASARTAN TRIHYDRATE POTASSIUM

 

General Information:

Fimasartan Potassium is an anti- hypertensive agent comes under the therapeutic category of Anti-hypertensive and consider as an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It was also approved by the Korea Food & Drug Administration (KFDA). Antihypertensive capture a huge market size in India as well as in export countries too.It is a pyrimidine-4(3H)-one derivative of losartan and provides a higher potency and stronger efficacy than losartan with a quick onset of antihypertensive effect. Fimasartan is the ninth and latest ARB for the treatment of hypertension.

 

Therapeutic Category:

FimasartanTrihydrate Potassium falls under the Anti –Hypertensive drugs category.

 

Primary Characterstics:

IUPAC Name:

2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide;trihydrate

Molecular Formula:

C27H36KN7O4S

Molecular Weight:

593.8g/mol  

Molecular Structure:

 

Mechanism of Action:

FimasartanTrihydrate Potassium acts on the kidney's rennin-angiotensin cascade, which begins when renin release from the kidney causes the breakdown of angiotensinogen into angiotensin IAngiotensin-converting enzyme (ACE) then catalyzes the reaction that forms angiotensin II, which acts on AT1 receptors on the blood vessels, heart, and kidneys.[5] On blood vessels, the AT1 receptor is coupled to an intracellular pathway that causes smooth muscle contraction (vasoconstriction) of blood vessels.[6] In blocking the AT1 receptor, fimasartan inhibits vasoconstriction, favouring vasodilation. At the kidney and adrenal gland, AT1 blockage and prevention of aldosterone formation increase excretion of water and salt by the kidneys, which decreases overall blood volume.[7] At the heart, AT1 blockage decreases contractility and the stimulatory effects of the sympathetic nervous system.[4] Collectively, fimasartain leads to a reduction in blood pressure and alleviation of hypertensive symptoms.